Membranous and soluble forms of Fas antigen in cutaneous lupus erythematosus

Journal of Dermatology

Volumn 25, Issue 5, 1998, Pages 302-308

  Fushimi, Misao ^a,b   Furukawa, Fukumi ^a   Tokura, Yoshiki ^a   Itoh, Taisuke ^a   Shirahama, Shigeho ^a   Wakita, Hisashi ^a   Takigawa, Masahiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

Author keywords

Apoptosis; Cutaneous lupus erythematosus; Fas antigen; Soluble Fas

Indexed keywords

FAS ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HISTOCHEMISTRY; HUMAN; MALE; MONONUCLEAR CELL; SKIN LUPUS ERYTHEMATOSUS;

EID: 0031862537     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1998.tb02402.x     Document Type: Article

References (29)

1. Nagata S: Fas and Fas ligand: A death factor and its receptor, Adv Immunol, 57: 129-144, 1994.
2. Peter ME, Kishokel FC, Hellbardt S, Chinnaiyan AM, Krammer PH, Dixit VM: CD95(APO-1/Fas)-associating signaling proteins, Cell Death Diff, 3: 161-170, 1996.
3. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jehkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis, Nature, 356: 314-317, 1992.
4. Ju S-T, Panka DJ, Gui H, et al: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature, 373: 444-448, 1995.
5. Brunner T, Mogil RJ, LaFace D, et al: Cell-autonomous Fas(CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas, Nature, 373: 441-444, 1995.
6. Cheng J, Zhou T, Liu C, et al: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule, Science, 263: 1759-1762, 1994.
7. Furukawa F, Tokura Y, Matsushita K, et al: Selective expansion of T cells expressing Vβ8 and Vβ13 in skin lesions of patients with chronic cutaneous lupus erythematosus, J Dermatol, 23: 670-676, 1996.
8. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 25: 1271-1277, 1982.
9. Urowitz MB, Gladmann DD, Tozman ECS, Goldsmith CH: The lupus activity criteria count (LACC), J Rheumatol, 11: 783-787, 1984.
10. Furukawa F, Kanauchi H, Imamura S: Susceptibility to UVB light in cultured keratinocytes of cutaneous lupus erythematosus, Dermatology, 189 (suppl 1): 18-23, 1994.
11. Wakita H, Tokura Y, Furukawa F, Takigawa M: Staphylococcal enterotoxin B upregulates expression of ICAM-1 molecules on IFN-γ-treated keratinocytes and keratinocyte cell lines, J Invest Dermatol, 105: 536-542, 1995.
12. Furukawa F, Kanauchi H, Wakita H, et al: Spontaneous autoimmune skin lesions of MRL/n mice: Autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice, J Invest Dermatol, 107: 95-100, 1996.
13. Wakita H, Yodoi J, Masutani H, Toda K, Takigawa M: Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions, J Invest Dermatol, 99: 101-107, 1992.
14. Tamada Y, Takama H, Kitamura T, et al: Identification of programmed cell death in normal human skin tissues by using specific labeling of fragmented DNA, Br J Dermatol, 131: 521-524, 1994.
15. Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA: Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): Implications for the pathogenesis of photosensitive cutaneous lupus, J Invest Dermatol, 94: 77-85, 1990.
16. Furukawa F. Ikai K, Matsuyoshi N, Shimizu K, Imamura S: Relationship between heat shock protein induction and the binding of antibodies to the extractable nuclear antigens on cultured human keratinocytes. J Invest Dermatol, 101: 191-195, 1993.
17. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes, J Exp Med, 179: 1317-1330, 1994.
18. Oishi M, Maeda K, Sugiyama S: Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell cartinoma cell lines, Arch Dermatol Res, 286: 396-407, 1994.
19. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ viva specific labeling of nuclear DNA fragmentation, J Cell Biol, 119: 493-501, 1992.
20. Nakajima M, Nakajima A, Kayagaki N, Honda M, Yagita H, Okumura K: Expression of the Fas and Fas ligand and its receptor in cutaneous lupus: Implication in tissue injury, Clin Immunol Immunopathol, 83: 223-229, 1997.
21. Amasaki Y, Kobayashi S, Takeda T, et al: Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia, Clin Exp Immunol, 99: 245-250, 1995.
22. Mysler E, Bini P, Drappa J, et al: The apoptosis-1/Fas protein in human systemic lupus erythematosus, J Clin Invest, 93: 1029-1034, 1994.
23. Ohsaka S, Hara M, Harigai M, Fukusawa C, Kashiwazaki S: Expression and function of Fas antigen and Bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol, 73: 109-114, 1994.
24. Jodo S, Kobayashi S, Kayagaki N, et al: Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases, Clin Exp Immunol, 107: 89-95, 1997.
25. Mounts JD, Pierson MC, Zhou T, et al: sFas expression in patients with autoimmune disease, Arthritis Rheum, 38 (s174): 127 (abstr), 1995.
26. Papo T, Ortora M, Piette JC, Frances C, Autran B, Gorochr G: High expression of soluble Fas by mononuclear cells of systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (PAPS) patients, Arthritis Rheum, 38: 210 (Abstr), 1995.
27. Knipping E, Krammer PH, Onel KB, Lehman TJA, Myler E, Elkon KB: Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis, Arthritis Rheum, 38: 1735-1737, 1995.
28. Goel N, Ulrich DT, St. Clair EW, Fleming JA, Lynch DH, Seldin MF: Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease, Arthritis Rheum, 38: 1738-1743, 1995.
29. Elkon KB, Marshak-Rothstein A: B cells in systemic autoimmune disease: Recent insights from Fas-deficient mice and men, Curr Opinion Immunol, 8: 852-859, 1996.